

Advances in Locally Advanced and Metastatic Kidney Cancer

Guest Editors:

Dr. Nirmish Singla

The Brady Urological Institute,
Johns Hopkins University School
of Medicine, Baltimore, MD
21287, USA

Dr. Yasser Ged

Department of Medicine, Johns
Hopkins University School of
Medicine, Baltimore, MD 21205,
USA

Deadline for manuscript
submissions:


15 April 2025

Message from the Guest Editors

Advanced renal cell carcinoma (RCC) exhibits a wide clinical spectrum, ranging from non-metastatic, high-risk or locally advanced tumors, to oligometastatic disease, to more widely disseminated metastatic involvement. In the locally advanced space, increasing interest has turned to administering systemic therapies in the perioperative (neoadjuvant or adjuvant) setting to help reduce recurrence. In the study of oligometastatic disease, new approaches to the locoregional management of metastatic sites, such as stereotactic radiation, have been employed to delay or obviate the need for systemic therapy while minimizing morbidity. In more widely disseminated diseases, novel therapeutic agents and rational combinations continue to emerge for both clear cell and non-clear cell RCC histologies. The role and timing for cytoreductive nephrectomy in metastatic disease continue to evolve, and the ideal setting remains unknown at present.

In this Special Issue, we are seeking high-quality, novel work highlighting advances in locally advanced and metastatic kidney cancer, pertaining to the themes delineated above. We look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)